L'intérêt à découvert pour AbbVie donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de AbbVie. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

AbbVie (NYSE:ABBV) Stock, Rapport sur les intérêts à découvert

AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

AbbVie Inc

Guggenheim analyst Vamil Divan reiterates AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Buy and maintains $214 price target.

News

Price Target

Reiteration

Analyst Ratings

ABBV

Guggenheim Reiterates Buy on AbbVie, Maintains $214 Price Target

US President Donald Trump issued a multi-part executive order on Tuesday to lower drug prices and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">reduce Medicare costs</a>.
Within 60 days, the Secretary of Health and Human Services is instructed to seek guidance for the Medicare Drug Price Negotiation Program for initial price applicability year 2028 and how drugmakers should implement the set prices in 2026, 2027, and 2028.
<ul>
<li>This guidance will focus on greater transparency, selecting high-cost drugs, and safeguarding pharmaceutical innovation.</li>
<li>Additionally, the administration seeks to eliminate a key disparity in how Medicare treats small-molecule drugs compared to biologics, discouraging investment in more affordable treatments.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
The White House is also <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/" rel="noreferrer noopener">targeting</a> the rising costs seniors face under Medicare. A new payment model will be tested within a year to obtain better value for high-cost drugs and biologicals, including those not subject to price negotiations.
Further, the administration wants to align Medicare payments with actual hospital acquisition costs through a national survey, with potential reimbursement adjustments following the results.
To reform Medicaid drug pricing, the administration will develop recommendations linking drug payments to their value and ensuring accurate rebate payments from manufacturers. The initiative also aims to assist states in managing spending while promoting innovation in Medicaid reimbursement.
Affordability for life-saving medications is another key focus: Community health centers will be required to offer insulin and epinephrine at or below discounted 340B prices to low-income individuals with high out-of-pocket costs or no insurance, with compliance tied to eligibility for future federal grants..
To address price manipulation in the supply chain, the administration calls for reevaluating middlemen roles, such as pharmacy benefit managers, and seeking transparency in their compensation structures. Within 90 days, recommendations to promote a more efficient pharmaceutical market are expected.
Other planned reforms include accelerating FDA approvals for generics and over-the-counter conversions, streamlining the drug importation program, and ensuring Medicare payments do not incentivize hospital-based care over less costly physician offices.
Lastly, federal agencies will investigate anti-competitive practices by drug manufacturers, with public listening sessions and policy recommendations expected within six months.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44826592/netflix-wants-to-be-the-next-1-trillion-company-analyst-highlights-growth-path" target="_blank" rel="noreferrer noopener">Netflix Wants To Be The Next $1 Trillion Company, Analyst Highlights Growth Path</a></li>
</ul>
Photo by Aria Armoko via Shutterstock

Biotech

Government

Regulations

Health Care

General

BIIB

BMRN

GILD

REGN

VRTX

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction

Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie.
Looking at options history for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 62% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $316,131 and 5, calls, for a total amount of $572,360.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $80.0 to $200.0 for AbbVie over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for AbbVie's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale activity within a strike price range from $80.0 to $200.0 in the last 30 days. 
<h3>AbbVie Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744725660_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$100.0</td>
<td>$98.05</td>
<td>$100.0</td>
<td>$80.00</td>
<td>$340.0K</td>
<td>0</td>
<td align="right">34</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.69</td>
<td>$1.68</td>
<td>$1.68</td>
<td>$150.00</td>
<td>$151.6K</td>
<td>3.6K</td>
<td align="right">1</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.34</td>
<td>$2.18</td>
<td>$2.33</td>
<td>$155.00</td>
<td>$108.3K</td>
<td>2.3K</td>
<td align="right">0</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$10.55</td>
<td>$10.3</td>
<td>$10.3</td>
<td>$175.00</td>
<td>$103.0K</td>
<td>3.0K</td>
<td align="right">68</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$28.25</td>
<td>$27.5</td>
<td>$28.08</td>
<td>$200.00</td>
<td>$56.1K</td>
<td>998</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>Current Position of AbbVie</h3>
<ul>
<li>Currently trading with a volume of 559,562, the ABBV's price is up by 1.11%, now at $179.44. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 10 days.</li>
</ul>
<h3>What The Experts Say On AbbVie</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $217.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on AbbVie, which currently sits at a price target of $241. 
&#x2A; In a cautious move, an analyst from Goldman Sachs downgraded its rating to Neutral, setting a price target of $194. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AbbVie, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

AbbVie Options Trading: A Deep Dive into Market Sentiment

President Donald Trump's announcement on Wednesday of a 90-day pause on tariffs against America's trading partners gave the market a short-lived relief. Experts believe market volatility is expected to continue as Trump <a href="https://www.usatoday.com/story/news/politics/2025/04/10/trump-tariffs-trade-war-stock-market-live-updates/83008953007/">raised</a> duties against China to 145% after Beijing responded with retaliatory tariffs. In this environment, investors are flocking to quality dividend stocks for downside protection.
Data from S&amp;P Global<a href="https://www.spglobal.com/spdji/en/documents/research/research-a-case-for-dividend-growth-strategies.pdf"> shows</a> from Dec. 31, 1999, to March 31, 2022, when the market was down, the S&amp;P High Yield Dividend Aristocrats outperformed the S&amp;P Composite 1500 by an average of 140 bps per month.
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
Last month, an investor from Germany <a href="https://www.reddit.com/r/dividends/comments/1jhijv4/felt_like_sharing_34m/">shared</a> his income report and portfolio details on r/Dividends, a Reddit community with more than 700,000 followers.&nbsp; The screenshots shared by the investor, 34, showed his monthly dividend income stood at €3,120 ($3,490). He said a part of his wealth came from inheritance.
"I make about 10k net with salary, business and capital gains," he said.
The investor also urged Redditors to save and keep costs in control.
"Be lucky &#8211; success in investment is mostly no function of work dedicated towards it. Save relentlessly. It might sound simple but putting aside 1,000 EUR per Month is 12k per year, putting aside 3, 000 EUR per month is a quite considerable 40k."
Trending: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.
Let's take a look at some of the key holdings in the portfolio.
Global X Nasdaq 100 Covered Call ETF
Global X Nasdaq 100 Covered Call ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QYLD#NASDAQ">QYLD</a>) is a notable ETF that earns money by selling covered call options on the Nasdaq-100 Index. The fund was started in 2013 and has since paid monthly income to investors. The fund yields about 13%. Some of the top holdings of the ETF are Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>).
Vanguard FTSE All-World High Dividend Yield UCITS ETF&nbsp;
The Vanguard FRESE All-World High Dividend Yield ETF focuses on companies that pay higher-than-average dividends, excluding REITs. JPMorgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) and AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) are among the fund's top holdings.
Vanguard FTSE All-World UCITS ETF&nbsp;
Vanguard FTSE All-World ETF tracks the FTSE All-World Index and gives investors exposure to large- and mid-cap companies in the developed and emerging markets.&nbsp;
Over 60% of the fund's portfolio is allocated to US stocks
See Also: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Deutsche Telekom
German telecommunications giant Deutsche Telekom was a part of the portfolio of the investor making about $3,400 a month in dividends. The investor said the company was among the "superb" performers for him and accounted for a "considerable" part of his portfolio. Deutsche Telekom has a dividend yield of about 2.6%.&nbsp;
Allianz
Germany-based financial services and insurance company Allianz has a dividend yield of over 4%. The stock has gained about 21% so far this year.
Amazon&nbsp;
Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) was among the non-dividend-paying stocks in the portfolio. The e-commerce giant's shares have lost about 13% in value so far this year amid broader market uncertainty.&nbsp;
Nike
Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) has a dividend yield of 2.7%. The stock is getting clobbered this year, down 20% through April 10, amid Trump's tariffs on imports from Asian countries. A major chunk of the company's products are manufactured in Vietnam.&nbsp;
Read Next:
<ul>
<li>Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Personal Finance

AAPL

AMZN

AVGO

MSFT

NVDA

QYLD

34-Year-Old Making $3,400 a Month in Dividends Shares His Top 7 Stocks — 'Be Lucky and Save Relentlessly'

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/04/11/final-trades-tjx-meta-abbvie-and-taiwan-semi.html">Halftime Report Final Trades</a>,&#8221; Kevin Simpson of Capital Wealth Planning said The TJX Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) is a standout name in a tough retail environment. It has solid earnings, free cash flow and great <a href="https://www.benzinga.com/quote/META/analyst-ratings">balance sheet, he added.</a>
Supporting his view, Citigroup analyst Paul Lejuez, on April 3, upgraded TJX Companies from Neutral to Buy and raised the price target from $128 to $140.
Brenda Vingiello of Sand Hill Global Advisors said Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) will be a winner in the overall advertising space.
On Friday, UBS analyst Lloyd Walmsley maintained Meta Platforms with a Buy rating and lowered the price target from $786 to $650.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Stephen Weiss of Short Hills Capital Partners picked Taiwan Semiconductor Manufacturing Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
President Donald Trump said on Sunday that he would reveal the tariff rate on imported semiconductors in the coming week, suggesting that excluding smartphones and computers from reciprocal tariffs in China might be temporary.
Jim Lebenthal of Cerity Partners named AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) his final trade.
Lending support to his choice, Morgan Stanley analyst Terence Flynn maintained AbbVie with an Overweight rating on April 9 and raised the price target from $239 to $241.
Price Action:
<ul>
<li>TJX shares gained 0.5% to close at $128.15 on Friday.</li>
<li>Meta shares fell 0.5% to close at $543.57 during Friday's session.</li>
<li>Taiwan Semiconductor Manufacturing shares gained 3.9% to close at $157.08 on Friday.</li>
<li>AbbVie gained 0.5% to settle at $175.05 during Friday's session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/44759831/top-3-industrials-stocks-that-may-explode-in-april">Top 3 Industrials Stocks That May Explode In April</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Media

Trading Ideas

Meta, TJX, Taiwan Semiconductor Manufacturing And A Health Care Stock: CNBC's 'Final Trades'

Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) revealed 20 unusual trades.
Delving into the details, we found 45% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 11 were puts, with a value of $503,310, and 9 were calls, valued at $449,277.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $220.0 for AbbVie during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in AbbVie's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to AbbVie's substantial trades, within a strike price spectrum from $130.0 to $220.0 over the preceding 30 days.
<h3>AbbVie Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744401665_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/02/25</td>
<td>$6.15</td>
<td>$5.8</td>
<td>$6.1</td>
<td>$175.00</td>
<td>$118.9K</td>
<td>13</td>
<td align="right">263</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$11.7</td>
<td>$11.65</td>
<td>$11.65</td>
<td>$175.00</td>
<td>$102.5K</td>
<td>2.0K</td>
<td align="right">135</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$12.9</td>
<td>$12.75</td>
<td>$13.06</td>
<td>$165.00</td>
<td>$72.8K</td>
<td>279</td>
<td align="right">84</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$10.85</td>
<td>$10.8</td>
<td>$10.72</td>
<td>$180.00</td>
<td>$54.0K</td>
<td>2.3K</td>
<td align="right">78</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$11.3</td>
<td>$11.25</td>
<td>$11.3</td>
<td>$155.00</td>
<td>$51.9K</td>
<td>611</td>
<td align="right">62</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>Present Market Standing of AbbVie</h3>
<ul>
<li>With a trading volume of 6,292,250, the price of ABBV is up by 0.78%, reaching $175.56.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 14 days from now.</li>
</ul>
<h3>What The Experts Say On AbbVie</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $217.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for AbbVie, targeting a price of $241. 
&#x2A; An analyst from Goldman Sachs has revised its rating downward to Neutral, adjusting the price target to $194. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AbbVie, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

AbbVie Unusual Options Activity

Omeros Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) on Thursday established the Omeros Oncology Clinical Steering Committee to advance Omeros&#8217; OncotoX biologics program focused on <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">acute myeloid leukemia (AML)</a>.
AML is the most fatal form of leukemia. It accounts for approximately 80% of acute leukemias in adults and one-third of all cancers <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44733942/omeros-announces-the-omeros-oncology-clinical-steering-committee-for-aml-to-help-guide-omeros-prop" rel="noreferrer noopener">affecting the blood/bone marrow</a>.
Omeros&#8217; OncotoX program for AML consists of proprietary targeted, engineered molecules (about half the size of an antibody) that deliver a toxic payload within the cancer cells, thereby killing them.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42598739/omeros-antibody-improves-overall-survival-in-rare-complication-after-stem-cell-transplant-stock-surges" rel="noreferrer noopener">Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges</a>
The steering committee will assist Omeros with developing the OncotoX-AML program, designing clinical trials, and interacting with institutional review boards, and it will also participate in OncotoX-AML clinical trials.
In vivo&nbsp;and&nbsp;ex vivo&nbsp;studies have shown that the OncotoX-AML therapeutic is highly effective even at very low doses, providing a significant survival benefit over currently approved combination therapy, like AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Genentech&#8217;s Venclexta (venetoclax) and Bristol Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Vidaza azacitidine).
In studies using primary AML derived from patients, the OncotoX molecule preferentially and efficiently kills AML blasts (abnormal myeloid cells).
OncotoX-AML also targets leukemia stem cells (LSC), often refractory to chemotherapy.
The OncotoX-AML therapeutic is designed specifically to kill both AML blasts and LSCs that can lead to relapse.
Preliminary&nbsp;in vivo&nbsp;tolerability studies demonstrate that the OncotoX therapeutic is well tolerated at doses substantially greater than one order of magnitude above efficacious doses without causing neutropenia or meaningful changes in blood chemistry values.
Omeros is initiating IND-enabling work for its OncotoX-AML therapeutic.
D. Boral analyst Jason Kolbert writes, &#8220;This development is particularly important given the persistent challenges in AML treatment. Despite recent drug approvals, therapeutic options for AML remain limited, especially for patients who are elderly, relapse-prone, or harbor high-risk mutations.&#8221;
Kolbert adds that chemotherapy and existing antibody-drug conjugates often fail to provide durable responses due to narrow therapeutic indices and toxic side effects. By demonstrating high efficacy in preclinical models without significant toxicity, OncotoX-AML presents the potential to address long-standing gaps in AML care.
The analyst maintains a Buy rating on Omeros with <a target="_blank" href="https://www.benzinga.com/quote/OMER/analyst-ratings" rel="noreferrer noopener">a price target of $36</a> while modeling Omeros&#8217; lead therapy, narsoplimab.
In February, the company resubmitted biologics license application for narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Omeros expects the target date for FDA action under the Prescription Drug User Fee Act to be six months following the date of resubmission to the FDA, meaning, in this case, the PDUFA date would be<a href="https://www.benzinga.com/pressreleases/25/03/b44570592/omeros-corporation-reports-fourth-quarter-and-year-end-2024-financial-results" target="_blank" rel="noreferrer noopener"> September 2025</a>.
The company expects to submit our European marketing authorization application for narsoplimab in TA-TMA in the first half of 2025.&nbsp;
Price Action: OMER stock is up 13.2% at $6.64 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44770461/intel-on-slump-as-china-hits-us-made-chips-with-tariffs-amd-and-taiwan-semiconductor-rise-on-exemption-boost" target="_blank" rel="noreferrer noopener">China Hits US-Made Chips With Tariffs, But Those Outsourcing To Taiwan Semiconductor Exempt</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Analyst Color

Movers

OMER

RHHBY

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

CNBC Halftime Report Final Trades: Meta Platforms, TJX Companies, AbbVie, Taiwan Semiconductor Manufacturing

Even as President Donald Trump paused the reciprocal tariffs for 90 days on Wednesday, he later confirmed in a conversation with reporters at his Oval Office that pharmaceutical companies would face tariffs.
What Happened: The rally in pharma stocks was short-lived after the stocks reversed course on Thursday. When a reporter asked President Trump if he would go ahead and levy tariff duties on pharmaceutical stocks, he said, &#8220;Yeah, well, I will be because we want them coming back.&#8221;
&#8220;You know, we realized during COVID-19 that we don&#8217;t make our drugs and our pharmaceuticals in this country. So, I realized that, and it was a big realization,&#8221; he added.
Citing the emergency during COVID-19, he stated that he wanted the pharma companies to produce drugs in the U.S.
&#8220;We had to go to China to get drugs, we had to go to other places, we don&#8217;t make it. That&#8217;s because we let them leave, and now if they want to come back, we&#8217;re going to put tariffs on the pharmaceutical companies, and they&#8217;re going to all want to come back,&#8221; Trump said.
The pharma stocks tumbled on Thursday after Trump&#8217;s confirmation of tariffs.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Pharma Stocks</td>
<td>Thursday&#8217;s Performance</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>-4.35%</td>
<td>-7.35%</td>
<td>-5.09%</td>
</tr>
<tr>
<td>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>-3.14%</td>
<td>-2.92%</td>
<td>3.99%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>-6.10%</td>
<td>-11.15%</td>
<td>2.73%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-5.26%</td>
<td>-23.60%</td>
<td>-40.63%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>-3.87%</td>
<td>-18.87%</td>
<td>-18.03%</td>
</tr>
<tr>
<td>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>-3.66%</td>
<td>10.36%</td>
<td>47.71%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-5.32%</td>
<td>-21.80%</td>
<td>-38.53%</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>-3.33%</td>
<td>8.54%</td>
<td>4.23%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>-1.51%</td>
<td>3.24%</td>
<td>-0.07%</td>
</tr>
</tbody>
</table>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/04/44755181/pentagon-slashes-5-1-billion-in-accenture-deloitte-booz-allen-contracts-thats-a-lot-of-consulting">Pentagon Slashes $5.1 Billion In Accenture, Deloitte, Booz Allen Contracts: &#8216;That&#8217;s A Lot Of Consulting&#8217;</a>
Why It Matters: Despite a 90-day pause on reciprocal tariffs, base global tariffs of 10% and China tariffs of 125%, along with sector-specific tariffs of 25% on steel and aluminum, auto, and auto parts remain in place. Adding to it, the President hinted that he could soon announce tariffs on pharmaceutical companies.
Here are some of the pharmaceutical industry-linked exchange-traded funds that could be impacted.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>-7.02%</td>
<td>-7.51%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-7.04%</td>
<td>-6.08%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-10.13%</td>
<td>-4.37%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-14.05%</td>
<td>-11.45%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>2.88%</td>
<td>0.35%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-11.54%</td>
<td>-10.18%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-41.35%</td>
<td>-43.86%</td>
</tr>
</tbody>
</table>
</figure>
Price Action: After Thursday&#8217;s fall, following Wednesday&#8217;s rebound, the Nasdaq 100 index was 17.46% lower than its previous high of 22,222.61 points. The S&amp;P 500 index was down 14.31% from its record of 6,147.43 points, and the Dow Jones declined 12.16% from its 52-week high of 45,073.63 points.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, ended lower on Thursday. The SPY was down 4.38% to $524.58, while the QQQ declined 4.25% to $446.18, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44728276/spy-qqq-call-volumes-spiked-minutes-before-tariff-pause-announcement-alexandria-ocasio-cortez-demands-disclosure-from-congress-members" target="_blank" rel="noreferrer noopener">SPY, QQQ Call Volumes Spiked Minutes Before Tariff Pause Announcement: Alexandria Ocasio-Cortez Demands Disclosure From Congress Members</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

AMGN

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies

Wall Street saw a tentative tech rebound early Wednesday, as investors begin to shrug off escalating U.S.-China trade tensions following <a href="https://www.benzinga.com/markets">a steep market selloff.</a>
After the Trump administration announced a dramatic hike in tariffs on Chinese goods to 104% starting Wednesday, Beijing retaliated with an 84% tariff on American products. U.S. Treasury Secretary Scott Bessent defended the aggressive trade stance, claiming the impact would ultimately backfire on China.
President Donald Trump took to Truth Social, writing, &#8220;BE COOL! Everything is going to work out well. The USA will be bigger and better than ever before!&#8221; 
He encouraged investors by stating, &#8220;this is a great time to buy, DJT,&#8221; likely referring to Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>), rather than the Dow Jones Transportation Index, which has dropped 18% since the tariff news broke.
Yet, broader risk sentiment remains subdued, with investors awaiting either a softer tone from the White House or a signal from the Federal Reserve—though both hopes appear to be fading.
By mid-morning in New York, tech stocks staged a rebound, lifting the Nasdaq 100 by 0.9%. Yet, the S&amp;P 500 and Dow Jones Industrial Average remained flat, while the Russell 2000 continued to underperform.
Meanwhile, U.S. Treasuries were failing to provide their traditional safe-haven support amid heightened uncertainty and volatility.
The 10-year Treasury yield surged 10 basis points to 4.40%, triggering a sharp selloff in medium- and long-dated bonds. The popular iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) dropped 1.8%, extending its three-day slide to 6.6%—its worst performance since March 2020.
Gold prices, on the other hand, soared over 3% to $3,075 per ounce, on track for their strongest daily gain since October 2023.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) also advanced, rising 1.4% to $77,289.
<h2 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>17,243.25</td>
<td>0.9%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>4,980.40</td>
<td>0.0%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>37,576.14</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,744.85</td>
<td>-1.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 11:25 a.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.3% up to $498.23.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) inched 0.1% up to $376.72.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 1% to $420.50.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.9% to $173.58</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 1.6%; the&nbsp;Utilities&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 1.9%.</li>
</ul>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Performers</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Last</th>
<th>Chg %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>)</td>
<td>38.43</td>
<td>7.11%</td>
</tr>
<tr>
<td>Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</td>
<td>82.60</td>
<td>5.62%</td>
</tr>
<tr>
<td>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)</td>
<td>18.97</td>
<td>4.62%</td>
</tr>
<tr>
<td>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>231.56</td>
<td>4.37%</td>
</tr>
<tr>
<td>Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>)</td>
<td>51.35</td>
<td>4.36%</td>
</tr>
<tr>
<td>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>179.89</td>
<td>4.33%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Worst 5 Losers</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Last</th>
<th>Chg %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>50.29</td>
<td>-5.24%</td>
</tr>
<tr>
<td>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>167.51</td>
<td>-4.64%</td>
</tr>
<tr>
<td>Alexandria Real Estate Equities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>)</td>
<td>73.55</td>
<td>-4.41%</td>
</tr>
<tr>
<td>Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)</td>
<td>33.49</td>
<td>-4.40%</td>
</tr>
<tr>
<td>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>)</td>
<td>54.50</td>
<td>-4.34%</td>
</tr>
</tbody>
</table>
</figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44710975/wall-streets-american-exceptionalism-trade-falters-as-dollar-stocks-bonds-all-slide">Wall Street&#8217;s &#8216;American Exceptionalism&#8217; Trade Falters As Dollar, Stocks, Bonds All Slide</a></li>
</ul>
Photo: Ryan DeBerardinis/Shutterstock

Sector ETFs

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

INCY

INTC

SWKS

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

Select Sector SPDR-Consumer Discretionary

Tech Stocks Rebound As US Treasuries Tumble: What's Driving Markets Wednesday?

Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Overweight and raises the price target from $239 to $241.

Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $241

Goldman Sachs analyst Asad Haider assumes AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Neutral rating and announces Price Target of $194.

Initiation

Goldman Sachs Assumes AbbVie at Neutral, Announces Price Target of $194

<ul>
<li>RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA)</li>
<li>The approval is supported by data from the pivotal Phase 3 SELECT-GCA trial which demonstrated that RINVOQ achieved the primary endpoint of sustained remission&#x2A; and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure and complete remission †1</li>
<li>This marks the eighth approved indication for RINVOQ in the EU2</li>
</ul>

AbbVie's RINVOQ Receives European Commission Approval As First And Only Oral JAK Inhibitor For Adults With Giant Cell Arteritis

Guidance

AbbVie Q1 2025 Earnings Include $248M IPR&D And Milestones Expense; For Q1 Sees Unfavorable Impact Of $0.13 To GAAP And Non-GAAP EPS; Q1 2025 Adjusted EPS Guidance $2.34-$2.38 Vs $2.51 Est.

President Donald Trump on Wednesday announced a slew of tougher-than-anticipated tariffs, but there are some <a href="https://www.whitehouse.gov/fact-sheets/2025/03/fact-sheet-president-donald-j-trump-addresses-the-threat-to-national-security-from-imports-of-timber-lumber-and-their-derivative-products/">notable exemptions</a> to the steep levies.&nbsp;
Here's a look at which products and sectors are excluded <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44626421/trumps-reign-of-tariffs-unleashes-d-day-on-wall-street-analyst-warns-of-stagflation-risk">from the reciprocal tariffs:&nbsp;</a>
Semiconductors: Semiconductors were exempted from the sweeping new tariffs due to their critical role in many technologies. However, the sector was deep in the red in Thursday's trading with shares of Broadcom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) down 6.78% and ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) down 3.69%.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44628368/trumps-tariffs-prompt-china-to-vow-countermeasures-experts-see-retaliation-likely">Trump&#8217;s Tariffs Prompt China To Vow &#8216;Countermeasures&#8217;: Experts See Retaliation Likely&nbsp;</a>
Pharmaceuticals: Trump excluded pharmaceuticals from the new tariffs, likely a relief for the industry that had been under pressure following the president's prior comments suggesting a 25% tariff on pharmaceutical imports.&nbsp;
"The United States can no longer produce enough antibiotics to treat our sick," Trump said Wednesday. "We have a tremendous problem, we have to go to foreign countries to treat our sick. If anything ever happened from a war standpoint, we wouldn't be able to do it."
Pharmaceutical stocks are defying Thursday's broad market drop with shares of AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) both in the green in mid-morning trading. 
Lumber: Lumber is another product excluded from Trump's tariff plan, for now. The administration said it is investigating how reliance on imported lumber impacts national security and economic stability. Exemptions have been granted to avoid immediate disruptions in supply chains critical to construction and defense in the meantime.&nbsp;
Gold, Copper: Certain metals and minerals including copper, gold and others not found in the U.S. were also exempted from the reciprocal tariff plan.&nbsp;
Gold dropped more than 3%, falling below $3,060 per ounce on Thursday after touching a new record high above $3,160. The SPDR Gold Trust ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), tracking the price of gold, was down only slightly, bucking the broader market declines.&nbsp;
Energy: Oil, gas and refined products imports were exempted from the sweeping new reciprocal tariffs, the White House said on Wednesday.&nbsp;
Shares of the United States Oil Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) fell 7.8% on Thursday, however, as the sweeping tariff plan could threaten global demand.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44537429/cathie-wood-doubles-down-on-2600-tesla-stock-price-prediction">Cathie Wood Doubles Down On $2,600 Tesla Stock Price Prediction</a></li>
</ul>
Photo: Shutterstock/Alones

Specialty ETFs

Commodities

Politics

Global

Economics

Tech

ASML

Trump's Tariff Exemptions Include Semiconductors, Pharmaceuticals, Oil And More

Investors with a lot of money to spend have taken a bearish stance on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 16 uncommon options trades for AbbVie.
This isn't normal.
The overall sentiment of these big-money traders is split between 31% bullish and 50%, bearish.
Out of all of the special options we uncovered, 10 are puts, for a total amount of $786,285, and 6 are calls, for a total amount of $289,665.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $185.0 to $215.0 for AbbVie over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for AbbVie's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale activity within a strike price range from $185.0 to $215.0 in the last 30 days. 
<h3>AbbVie 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743533132_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$2.61</td>
<td>$2.56</td>
<td>$2.56</td>
<td>$205.00</td>
<td>$151.8K</td>
<td>678</td>
<td>1.2K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/11/25</td>
<td>$2.7</td>
<td>$2.41</td>
<td>$2.7</td>
<td>$205.00</td>
<td>$113.9K</td>
<td>678</td>
<td>1.7K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.3</td>
<td>$5.15</td>
<td>$5.3</td>
<td>$200.00</td>
<td>$106.0K</td>
<td>4.8K</td>
<td>520</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$2.51</td>
<td>$2.5</td>
<td>$2.5</td>
<td>$205.00</td>
<td>$99.2K</td>
<td>678</td>
<td>7</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$9.35</td>
<td>$9.15</td>
<td>$9.28</td>
<td>$210.00</td>
<td>$92.7K</td>
<td>7.7K</td>
<td>148</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>AbbVie's Current Market Status</h3>
<ul>
<li>With a trading volume of 3,955,651, the price of ABBV is up by 0.66%, reaching $210.91.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 24 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for AbbVie</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $231.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on AbbVie, which currently sits at a price target of $240. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Neutral rating for AbbVie, targeting a price of $223. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AbbVie, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Looking At AbbVie's Recent Unusual Options Activity

Deep-pocketed investors have adopted a bullish approach towards AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ABBV usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 23 extraordinary options activities for AbbVie. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 43% leaning bullish and 21% bearish. Among these notable options, 16 are puts, totaling $1,740,435, and 7 are calls, amounting to $359,373.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $180.0 to $220.0 for AbbVie over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of AbbVie stands at 3048.78, with a total volume reaching 10,547.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in AbbVie, situated within the strike price corridor from $180.0 to $220.0, throughout the last 30 days.
<h3>AbbVie 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743447675_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$8.3</td>
<td>$8.1</td>
<td>$8.2</td>
<td>$185.00</td>
<td>$410.0K</td>
<td>114</td>
<td>500</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$3.15</td>
<td>$3.0</td>
<td>$3.05</td>
<td>$195.00</td>
<td>$305.0K</td>
<td>2.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$5.5</td>
<td>$5.3</td>
<td>$5.3</td>
<td>$200.00</td>
<td>$161.6K</td>
<td>4.1K</td>
<td>327</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$4.05</td>
<td>$3.9</td>
<td>$3.97</td>
<td>$205.00</td>
<td>$134.9K</td>
<td>694</td>
<td>1.2K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$3.25</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$205.00</td>
<td>$91.4K</td>
<td>694</td>
<td>558</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
In light of the recent options history for AbbVie, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of AbbVie</h3>
<ul>
<li>Currently trading with a volume of 4,607,370, the ABBV's price is up by 1.79%, now at $208.96. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 25 days.</li>
</ul>
<h3>What The Experts Say On AbbVie</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $231.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on AbbVie with a target price of $240. 
&#x2A; An analyst from B of A Securities has decided to maintain their Neutral rating on AbbVie, which currently sits at a price target of $223. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AbbVie options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Decoding AbbVie's Options Activity: What's the Big Picture?

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/03/28/final-trades-paypal-meta-abbvie-and-snowflake.html">Halftime Report Final Trades</a>,&#8221; Malcolm Ethridge of CIC Wealth Management named PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) <a href="https://www.benzinga.com/25/02/43942860/paypal-eyes-double-digit-eps-growth-by-2027-teams-up-with-verifone-jp-morgan-more">his final trade</a>.
On Feb. 25, PayPal issued an outlook ahead of its Investor Day event. The company reiterated guidance for an adjusted EPS growth of 6%-10% and transaction margin dollar growth, excluding the impact of interest on customer balances of growth of at least 5%. The company expects high single-digit transaction margin dollar growth and low teens+ adjusted EPS growth by 2027.
Kevin Simpson of Capital Wealth Planning said Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is his top pick out of the Mag 7 names, having great free cash flow and huge margins.
On Friday, Citizens Capital Markets analyst Andrew Boone reiterated Meta Platforms with a Market Outperform rating and maintained a $750 price target.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Jim Lebenthal of Cerity Partners said AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is a stock in a nice uptrend. It has pulled back a little bit. It has a very attractive valuation, good management and good product pipelines, he added.
AbbVie released on March 15 the final analysis of the confirmatory Phase 3 MIRASOL trial of Elahere (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) compared to chemotherapy.
Stephanie Link picked Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>), down 23% from its highs.
As per the recent news, Snowflake, on March 6, appointed Mike Gannon as chief revenue officer.
Price Action:
<ul>
<li>PayPal shares dipped 5.4% to close at $65.15 on Friday.</li>
<li>Meta shares fell 4.3% to close at $576.74 during Friday's session.</li>
<li>AbbVie shares gained 1.3% to close at $205.29 on Friday.</li>
<li>Snowflake shares dipped 4.1% to settle at $150.63.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44534977/jim-cramer-healthpeak-properties-is-a-reasonable-reit-recommends-buying-this-health-care-stock">Jim Cramer: Healthpeak Properties Is A &#8216;Reasonable&#8217; REIT, Recommends Buying This Health Care Stock</a></li>
</ul>
Photo: Shutterstock

PYPL

SNOW

Meta, Snowflake, PayPal And Health Care Stock On CNBC's 'Final Trades'

CNBC Halftime Report Final Trades: PayPal Holdings, Meta Platforms, AbbVie, Snowflake

<a href="https://in.benzinga.com/personal-finance/25/03/44376666/high-yield-dividend-investor-making-12900-per-year-names-10-favorite-stocks-took-me-almost-3-years-to-get-to-this-point">Dividend</a> investing has long been a favorite strategy for retirees and income-focused investors. Unlike growth-oriented assets, which depend on share price appreciation, dividend-paying stocks generate regular payouts.
But why do so many investors run to dividend stocks and ETFs? Dividends offer a way to compound wealth by reinvesting the generated income while also providing financial stability in <a href="https://in.benzinga.com/personal-finance/25/03/44476778/author-says-dave-ramsey-is-completely-ignorant-of-sequence-of-returns-risk-questions-whether-1-million-is-really-enough-for-retirement">retirement</a>. High-quality dividend companies also have a history of increasing payouts year after year, helping investors keep up with inflation.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
Still, total returns are also important in investing, as one investor demonstrated. The investor, a Reddit user who shared his journey in the r/Dividends community, is a 61-year-old retiree who spent 37 years building his portfolio on growth before switching to a dividend strategy when approaching retirement. He ultimately crafted a portfolio yielding around 8% and named his top holdings in the thread.
&#8220;My big break was being mostly cash in early 2020 because I felt the market had gotten too expensive. That was largely luck but it worked great. March 2020 was really fun. I spent between $1 million to $2 million on stocks in about 30 days and the resulting market rise after that secured my retirement. When I started learning about dividends, I included it as one option but still looked at it from a perspective of total returns,&#8221; he shared.
Now, he lives comfortably off dividends, rarely selling stocks for income, and relying on growing dividend payouts. The investor has shared his holdings in the Reddit community, so let&#8217;s see what they are.
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a>
<h2 class="wp-block-heading">Retiree Living Off Dividends Shares Top 10 Holdings in Reddit Investing Community</h2>
AbbVie
AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is a global biopharmaceutical company focusing on the research and development of advanced treatments for complex diseases. Investors love ABBV because of its strong product portfolio and its steady dividend history, paying approximately 3.23% annually in dividends.
Arbor Realty Trust
A real estate investment trust with a high yield, Arbor Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABR#NYSE">ABR</a>) focuses on originating and servicing loans for multifamily and commercial real estate. The company pays investors around 14.11% in dividends annually.
Broadcom
A tech dividend grower, Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) is known for semiconductors and software, and despite a modest yield, it raises payouts aggressively. AVGO has a 1.24% dividend yield per year.
Hercules Capital
Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) is a business development company that offers venture debt to technology and life sciences companies. Investors love HTGC since it offers high dividend yields and exposure to emerging growth companies. The company pays investors around 9.39% in dividends.
Mastercard
Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) is a well-known global technology company operating in the payments industry. MA pays investors approximately 0.56% in dividends yearly.
See Also: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Realty Income Corporation
A real estate investment trust, Realty Income Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) is known as &#8220;the monthly dividend company&#8221; since it pays investors every month. O owns over 6,500 properties under long-term lease agreements and has a very diversified property portfolio, paying 5.76% per year in dividends.
Target
Operating as a general merchandise retailer selling a wide assortment of products, such as household essentials, apparel, and electronics, Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) generates approximately 4.23% in dividends.
Vanguard Total Stock Market ETF
Vanguard Total Stock Market ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTI#NYSE">VTI</a>) tracks the performance of the CRSP US Total Market Index, covering virtually all investable U.S. stocks. With a dividend of around 1.35% per year, the ETF is loved by investors because it offers broad exposure to the U.S. equity market with low expense ratios.​
Schwab U.S. Dividend Equity ETF
Tracking the performance of the Dow Jones U.S. Dividend 100 Index, Schwab U.S. Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>) focuses on high-dividend-yielding U.S. stocks. SCHD generates around 3.81% in dividends.
Invesco S&amp;P SmallCap 600 Revenue ETF
Paying around 1.47% in dividends per year, Invesco S&amp;P SmallCap 600 Revenue ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RWJ#NYSE">RWJ</a>) tracks the performance of the S&amp;P SmallCap 600 Revenue-Weighted Index. Investors love RWJ because it provides exposure to small-cap U.S. companies weighted by earnings.
Read Next:
<ul>
<li>Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

HTGC

SCHD

Retired At 58, He 'Spent Between $1M-$2M On Stocks' – Investor Who Built An 8% Yield Portfolio And Lives Off Dividends Shares Top Holdings

Press Releases

ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients

Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025

AbbVie to Host First-Quarter 2025 Earnings Conference Call

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis

New York Plastic Surgical Group and Deep Blue Med Spa Receive State and National Recognition by Allergan Aesthetics

ABBV LAWSUIT ALERT: The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Legal

Investors who lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact The Gross Law Firm about pending Class Action - ABBV

Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

AVIR

CARM

COYA

MEIP

RIBT

SYBX

TSX:PHO

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Comments

AbbVie

Intérêt court

AbbVie (NYSE:ABBV) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL